公司資料
Artelo Biosciences 股價、新聞與催化劑
- 股票代碼:
- ARTL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.72 USD (-8.76%)
收盤價
最後更新: 2026年8月17日
5.05M USD
市值
股價為何變動
Following the latest company update, “Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies”, ARTL closed down 8.76% at $0.7210 on Aug 17, 2026. The move occurred in the trading session associated with this clinical readout update.
公司概覽
Lipid-Signaling Therapeutics
Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms.
ART27.13
ART27.13 is a peripherally selective cannabinoid-receptor agonist in Phase 2 development for cancer anorexia-cachexia syndrome. The goal is to improve appetite, weight, lean body mass and activity without central psychoactive effects.
ART26.12
ART26.12 is a fatty-acid-binding-protein 5 inhibitor being developed as a non-opioid, non-steroidal analgesic, initially for chemotherapy-induced peripheral neuropathy. A Phase 1 single-ascending-dose study showed favorable safety and predictable pharmacokinetics.
ART12.11
ART12.11 is a proprietary cocrystal of cannabidiol and tetramethylpyrazine designed to improve the pharmaceutical properties of CBD. Preclinical work supports potential development in anxiety or depression-related indications.
未來催化劑
- Initiation of a Phase 1 multiple-ascending-dose study of ART26.12 in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。